PROFOS closes financing round with additional EUR 2 Million

Wednesday, 24. May 2006 11:00

Regensburg, Germany, May 2006 - The leading German biotech company
Profos AG continues to achieve momentum: today the company announced
that Bayern Kapital and KfW have entered into a participation
agreement with the Company which provides for an investment of EUR 1
million each within the second closing of the Company's current
financing round, supplementing the EUR 5 million first closing
investments from Bio Fund Management Ltd., Helsinki, Danisco Venture
A/S, Copenhagen and Capital Stage AG, Hamburg in July 2005.

Profos will use the raised capital to continue the commercialisation
process, to expand its production plant and to accelerate the
development of its cutting edge technologies in bacteria detection
and endotoxin removal with its proprietary phage technology. The
Company's focus for the next years is on the one hand the Food Safety
Testing where the patented technology is the basis for the fast and
reliable testing of several different foods as meat or cheese. The
second immediate application of the Company's technology is the
detection and removal of endotoxins (with its already successful
Product EndoTrap®) which are known to a broad public as the major
cause for human sepsis.

"The competence and experience of our investors is helping us to
reach major successes in our business development and we feel that
the value of our industry position is greatly enhanced by the support
of our investors and board of directors", commented Dr. Wolfgang
Mutter, CEO of Profos.

Oliver Glück, CFO, emphasised the importance of this second closing:
"We highly appreciate the investment decisions of our new investors
in the current unfavourable environment for Biotech companies since
they demonstrate the confidence in the Company's further prospects
and equity story. With this solid financial base Profos is able to
reach its business goals. The strong demand and increasing inquiries
of potential customers and industrial partners underline the
outstanding chances for a successful commercialisation."

Bayern Kapital Risikokapitalbeteiligungs GmbH (Landshut, Germany) is
a Bavarian venture capital company with the objective to finance
research and market introduction of innovative products mainly in the
fields of life Science, software and information/communication
technology. Bayern Kapital is an essential driver of financing
innovation projects in Bavaria. Since its foundation in 1995 the
company has co-financed over 130 promising Bavarian start-ups, many
of which have been able to achieve good market positions with
excellent prospects.

KfW (Frankfurt, Germany) is a bank supported by the German government
that offers loans, mezzanine, financing, equity capital and
consulting services to e.g. small and medium sized enterprises. As a
source of impulses it is furthermore the task of KfW to support
companies that are working on new, promising technologies, not only
with financing but also in their search for venture capital.

-----------------------------------------

For further information please contact:

Profos AG. www.profos.de
Dr. Wolfgang Mutter, CEO
Tel +49 - (0)941 - 942 62 24. E-Mail: wolfgang.mutter@profos.de

Bayern Kapital Risikokapitalbeteiligungs GmbH. www.bayernkapital.de
Monika Steger, Senior Investmentmanager
Tel +49 - (0)871-923 25 19 E-Mail: Steger@bayernkapital.de

KfW. www.kfw-mittelstandsbank.de
Markus Danhausen, Senior Investmentmanager
Tel +49 - (0)228 831 - 7905 E-Mail: Markus.Danhausen@KfW.de



-------------------------------------------
Related Links: 
Author:
Hugin
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.